Cargando…
Low-dose urokinase thrombolytic therapy for patients with acute intermediate-high-risk pulmonary embolism: A retrospective cohort study
INTRODUCTION: Patients at intermediate-high risk of developing a pulmonary embolism (PE) are very likely to experience adverse outcomes, such as cardiovascular instability and death. The role of thrombolytic therapy in intermediate-high-risk PE remains controversial. OBJECTIVES: This study aimed to...
Autores principales: | Weng, Cuilian, Wang, Xincai, Huang, Long, Lin, Xingsheng, Liu, Qinghua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997002/ https://www.ncbi.nlm.nih.gov/pubmed/33770113 http://dx.doi.org/10.1371/journal.pone.0248603 |
Ejemplares similares
-
Comparison of urokinase and reteplase thrombolytic treatment in patients with high-risk pulmonary embolism
por: Zhang, Yi, et al.
Publicado: (2019) -
Low-dose thrombolytic therapy versus unfractionated heparin in patients with intermediate-high risk pulmonary embolism
por: Surgit, Ozgur, et al.
Publicado: (2023) -
The thrombolytic effect of lumbrokinase is not as potent as urokinase in a rabbit cerebral embolism model.
por: Kim, J. S., et al.
Publicado: (1993) -
Comparing different thrombolytic dosing regimens for treatment of acute pulmonary embolism
por: Ghanem, Ammar, et al.
Publicado: (2010) -
The Efficacy and Safety of Intermittent Low-Dose Urokinase Thrombolysis for the Treatment of Senile Acute Intermediate-High-Risk Pulmonary Embolism: A Pilot Trial
por: Zhao, Tianming, et al.
Publicado: (2018)